Medicare beneficiaries who fill a GLP-1 weight-loss prescription through the new Medicare GLP-1 Bridge program will pay a flat $50 copay per month, but none of that spending will count toward the $2,100 out-of-pocket threshold that triggers catastrophic drug coverage in 2026. The distinction creates a financial blind spot for older adults who assume every dollar they spend on prescriptions brings them closer to the annual cap. Because the Bridge sits entirely outside the Part D benefit structure, patients could pay $50 a month for years without ever reducing their remaining distance to catastrophic protection.
How the $50 GLP-1 copay bypasses the Part D spending cap
The disconnect traces back to a single design choice by the Centers for Medicare and Medicaid Services. CMS guidance for Part D plan sponsors states that the GLP-1 Bridge “operates outside the Part D benefit payment flow.” That means no part of the $50 copay counts toward what CMS calls “true out-of-pocket costs,” or TrOOP, the running tally that determines when a beneficiary crosses into catastrophic coverage. The net price of the drug itself does not count toward gross covered prescription drug costs either, according to CMS guidance.
For 2026, CMS set the annual out-of-pocket threshold at $2,100, adjusted upward from the original $2,000 cap established by the Inflation Reduction Act using an annual percentage increase methodology, according to the Final CY 2026 Part D Redesign Program Instructions. Once a beneficiary’s TrOOP-eligible spending hits that mark, catastrophic coverage kicks in and cost-sharing drops sharply. The problem is straightforward: Bridge copays never move the needle on that counter.
A beneficiary taking a GLP-1 drug through the Bridge and also filling other Part D prescriptions will see only the Part D prescriptions accumulate toward the $2,100 ceiling. The $50 monthly Bridge payment functions more like a standalone fee than a traditional copay. Someone spending $600 a year on GLP-1 Bridge copays alone, for example, would still show zero progress toward catastrophic protection from those payments.
The distinction matters because Part D coverage is now built around a clear annual limit on what beneficiaries pay out of pocket. As explained in Medicare’s overview of Part D costs, TrOOP includes deductibles, copays, and coinsurance for covered drugs, along with certain manufacturer discounts. Spending on drugs that are not treated as Part D benefits does not count. By carving the GLP-1 Bridge out of the benefit payment flow, CMS ensured that the $50 copay would be treated as separate from this protection.
Separate program, separate rules for GLP-1 Bridge spending
The legal architecture behind this split is deliberate. The Part D Manufacturer Discount Program, created under 42 U.S.C. Section 1395w-114c and effective since January 2025, restructured how drug costs flow through the Part D benefit. The GLP-1 Bridge was built as a parallel channel, not as an extension of Part D. Medicare’s consumer-facing page confirms that the $50 copay belongs to “a separate Medicare program” and is “not regular Part D coverage,” as stated on Medicare’s weight-loss drug page.
This separation has a concrete consequence for beneficiaries who take expensive medications across both channels. A person filling a GLP-1 prescription through the Bridge while also paying for, say, insulin or cardiac drugs through Part D will see only the insulin and cardiac prescriptions counted toward TrOOP. Even if that person spends hundreds of dollars on Bridge copays over the course of the year, their official out-of-pocket total for purposes of the $2,100 cap will reflect only Part D-covered drugs and other TrOOP-eligible amounts.
In practice, that means a beneficiary could reach the catastrophic threshold later than expected, or not at all, despite substantial overall pharmacy spending. Someone who pays $150 a month in Part D copays and $50 a month through the Bridge will cross the $2,100 TrOOP line based solely on the $150 share. The additional $600 in annual GLP-1 payments simply never appears in the Part D accounting.
Because the Bridge is time-limited and structured as a transition tool, CMS framed it as a way to provide near-term access to GLP-1 weight-loss drugs without permanently redefining Part D’s benefit design. But the choice to wall off Bridge spending from TrOOP also shifts more financial risk to patients. Beneficiaries who assume “all prescription spending counts” could underestimate their potential exposure if they later need a high-cost cancer drug, biologic, or other specialty therapy covered under Part D.
Consumer advocates and plan counselors may need to emphasize this nuance when explaining the new cap. The headline promise of a $2,100 annual limit is accurate for TrOOP-eligible costs, yet incomplete for people who rely on the GLP-1 Bridge. To avoid surprises at the pharmacy counter, older adults using the program should track two figures: what they pay for Part D-covered prescriptions, which moves them toward catastrophic coverage, and what they pay through the Bridge, which does not. Understanding that split is essential to budgeting for care in 2026 and beyond.
